



June 17, 2024

BSE Limited

Department of Corporate Services,
P. J. Towers, Dalal Street,
Mumbai Samachar Marg,
MUMBAI - 400 001.

✓ **National Stock Exchange of India Limited**

Exchange Plaza,
Bandra Kurla Complex,
Bandra (East),
MUMBAI - 400 051.

Dear Sir/Madam,

Ref: Disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations').

Sub: Change in Senior Management

We are pleased to inform you about the appointment of Mr. Abdelaziz Toumi as Chief Executive Officer, effective June 17, 2024, of Lupin Manufacturing Solutions ('LMS'), newly formed subsidiary of the Company.

LMS is engaged in the development, manufacture and sale of Active Pharmaceutical Ingredients and is starting to build its Contract Development and Manufacturing Operations ('CDMO') business.

Disclosure in compliance with Regulation 30 read with Schedule III Part A Para A(7) of the Listing Regulations and SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, in respect of change in Senior Management is enclosed as **Annexure - 'A'**.

The above is for your information and dissemination.

Thanking you,

For LUPIN LIMITED

R. V. SATAM
COMPANY SECRETARY
(ACS -11973)

Encl: - Annexure - 'A'



ANNEXURE - 'A'

Particulars as per Regulation 30 read with Schedule III Part A Para A(7) of the Listing Regulations and SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023.

Sl. No.	Particulars	Description
1.	reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise.	<p>Appointment of Mr. Abdelaziz Toumi as Chief Executive Officer of Lupin Manufacturing Solutions ('LMS'), newly formed subsidiary of the Company.</p> <p>LMS is engaged in the development, manufacture and sale of Active Pharmaceutical Ingredients and is starting to build its Contract Development and Manufacturing Operations ('CDMO') business.</p>
2.	date of appointment/re-appointment/cessation & terms of appointment/re-appointment.	The appointment of Mr. Toumi is effective June 17, 2024 and is not for a fixed term.
3.	brief profile.	<p>Mr. Toumi is a seasoned leader with a blend of scientific and commercial skills and brings over two decades of rich experience in the biotech, pharma, and CDMO sectors, spanning Europe, North America, and Asia. He has held leadership positions at Bayer, Merck, Catalent, Lonza, and KBI Biopharma, where he was responsible for driving growth, innovation, and operational excellence. Mr. Toumi will be based in Switzerland and will spend considerable time in India.</p> <p>Mr. Toumi holds a doctorate in Chemical Engineering and a master's degree in Business Administration from the University of Southern Queensland.</p>
4.	disclosure of relationships between directors.	Not applicable as Mr. Toumi is not a Board Member of LMSL.

For LUPIN LIMITED

**R. V. SATAM
COMPANY SECRETARY
(ACS -11973)**